
ACHV Stock Forecast & Price Target
ACHV Analyst Ratings
Bulls say
Achieve Life Sciences is a financially sound company with a strong focus on research and development, as evidenced by the successful completion of a Phase 2 study for its lead product. The company also has a potentially valuable market segment for vaping cessation, which could provide a significant revenue stream. With experienced leadership and a promising product in the pipeline, Achieve Life Sciences has the potential for long-term success and growth in the pharmaceutical industry.
Bears say
Achieve Life Sciences is heavily dependent on the success and approval of cytisinicline, with a projected peak penetration in its initial target population of only 12% leading to net U.S. sales of ~$800 million, and the company's financials are heavily reliant on this drug's success. The company is also facing competition in the smoking cessation market, and any potential regulatory delays or lower than expected adoption rates could negatively impact the company's financial performance. Additionally, there have been concerns raised about the potential for nausea side effects with cytisinicline, which could limit patient compliance and affect the drug's sales and overall success in the market.
This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
ACHV Analyst Forecast & Price Prediction
Start investing in ACHV
Order type
Buy in
Order amount
Est. shares
0 shares